Pharma Focus Europe


The pharmaceutical industry demands a winning approach if you want to accomplish your goals. Pharmaceutical companies are required to develop effective drug development services as part of their evolution. The pharmaceutical industry is at the forefront of human knowledge when it comes to regulatory strategy and strategic developments. Businesses and organizations face many challenges due to their size and complexity. Conversely, implementing strategic development and distribution networks is very expensive. For this reason, effective pharmaceutical strategies are critical to achieving long-term success, as they allow for relationship building, market research, and corporate exposure.

Revolutionizing Medicine

The Pivotal Role of Artificial Intelligence in Drug Discovery and Medical Device Design

In the rapidly evolving landscape of healthcare and medical research, the advent of artificial intelligence (AI) has marked a transformative era,

Why are Generic Pharmaceutical Manufactures Leaving the USA?

In recent years, the United States has witnessed a remarkable phenomenon in the pharmaceutical industry

Strategic Partnerships in Biotech

Catalysts for Accelerated Innovation

Biotechnology, an industry at the forefront of scientific innovation and transformative healthcare solutions...

Strategic Navigation in the Evolving European Pharma Landscape: A Comprehensive Analysis

In the ever-evolving landscape of the European pharmaceutical industry, this article offers a comprehensive analysis of the strategic initiatives shaping the sector. From navigating regulatory complexities to exploring market trends,

Model-Informed Drug Development (MIDD) - EMA's Advancement

M&S is used in all phases of drug development in the EU, US, and UK starting from pre-clinical pharmacokinetic (PK) and pharmacokinetic/pharmacodynamics (PK/PD) studies, through clinical trials to post-marketing commitments.


If you’re not thinking ecosystems, you’re not thinking

To an ecologist, an ecosystem is a biological community of interacting organisms and their physical environment. This concept helps us to see that ecosystems in the life science industry are not simply sub-parts or the market or the industry. They have wide boundaries and those boundaries blur and overlap with other ecosystems.


A US perspective

When a pharmaceutical company first develops a new drug or any device to be used for the treatment of a disease, it is initially marketed under a brand name by which clinicians can recommend or prescribe the drug or any device for use by patients.

Biomedical Market Leaders

Learning to thrive

If you have worked in the biomedical industry for more than a couple of years, you will have noticed one of its most characteristic features: change. Pharma, medtech and related businesses operate in a complex environment of two halves: the sociological and the technological. Our sociological environment, including demography, epidemiology and poli...

Brexit and Pharmacovigilance

Where may pharmaceutical companies go?

What may happen to sick people should medicinal products suddenly not be available owing to Brexit? Some 45 million patient packs go to the European Union (EU) from the United Kingdom (UK) every month, with a further 37 million patient packs moving from the EU to the UK.



COVID-19 has posed an unprecedented threat to the health and economy globally since its first detection in December 2019 with more than 435 million cases and 5.9 million deaths (as of February 27,2022).


Four Strategic Instincts Separate Great Strategists from the Others

You are probably all-too-familiar with the rigmarole of strategic planning – situational analyses and spreadsheets, slide decks and strategy reviews.



One of the most important tasks of any regulatory body is to ensure that pharmaceutical products are developed in accordance with the local/regional regulatory requirements.

The Future of Tissue-Targeted Lipid Nanoparticle-Mediated Nucleic Acid Delivery

The earliest example of in vivo expression of exogenous mRNA was by direct intramuscular injection in mice without the aid of a delivery vehicle [1]. This appears to defy what is known about nucleic acids, being that they are large, polar and metabolically unstable drugs that do not cross cell membranes. However, since cytoplasmic delivery is essen...

Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024